ClinicalTrials.gg
CompletedNCT02324673Updated Jun 23, 2017Results posted

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

A Phase 1/2 interventional study of Cannabidiol Oral Solution in Seizures, sponsored by INSYS Therapeutics Inc. Completed at 10 sites in United States. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2017-06-23.

Sponsored by INSYS Therapeutics Inc · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing cannabidiol in Seizures — 2 open to participants now, 2 under way, none of them phase 3. Cannabidiol · Seizures.

Enrollment
7th of 13
61 · median 61
Started
2015
with 2 others
Phase 1/2
Only one
of the 13
Registered
2nd of 13
by date
Lead sponsor
2 of 13
INSYS Therapeutics Inc

Among the 13 studies testing cannabidiol in Seizures, this one is the 7th largest by enrollment, is one of 3 that started in 2015, is the only one in phase 1/2, and was the 2nd registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

2 of the 13 studies testing cannabidiol in Seizures are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing cannabidiol in Seizures, or all of them as a file.
02

Study summary

This is a Phase 1/2, open-label trial designed to assess the pharmacokinetics, safety, tolerability, and preliminary efficacy of 3 multiple ascending doses of Cannabidiol Oral Solution in a sequential fashion.

Participants will be pediatric (aged 1-17, inclusive), experiencing treatment-resistant seizures, and satisfy all inclusion/exclusion criteria.

03

Conditions studied

  • Seizures

Browse trials for

Keywords

  • Treatment-resistant seizures
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets protocol-specified criteria for qualification and , including treatment-resistant seizure disorder
  • Is able to speak and understand the language in which the study is being conducted, is able to understand the procedures and study requirements and has voluntarily signed and dated an form approved by the Institutional Review Board before the conduct of any study procedure
  • In the opinion of the Investigator, the participants and parent(s)/caregiver(s) are willing and able to comply with the study procedures and visit schedules, including venipuncture, inpatient stay at the study center, dosing at the study center twice a day as needed while an outpatient), and the Follow-up Visits (if applicable)

Exclusion criteria

Exclusion Criteria:

  • Participant or parent(s)/caregiver(s) have daily commitments during the study duration that would interfere with attending all study visits
  • History or current use of dietary supplements, drugs or over-the counter medications outside protocol-specified parameters
  • Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:

    1. the safety or well-being of the participant or study staff
    2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)
    3. the analysis of results
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Low Dose Cannabidiol Oral Solution [10 mg/kg/day]

    Low Dose \[10 milligrams/kilogram/day (mg/kg/day)\] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg/kg in the morning on Day 1 followed by total dose of 10 mg/kg/day (5 mg/kg in the morning and 5 mg/kg in the evening) on Days 4 to 10.

    Drug: Cannabidiol Oral Solution

  • Experimental
    Mid Dose Cannabidiol Oral Solution [20 mg/kg/day]

    Mid Dose \[20 mg/kg/day\] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg/kg in the morning on Day 1 followed by total dose of 20 mg/kg/day (10 mg/kg in the morning and 10 mg/kg in the evening) on Days 4 to 10.

    Drug: Cannabidiol Oral Solution

  • Experimental
    High Dose Cannabidiol Oral Solution [40 mg/kg/day]

    High Dose \[40 mg/kg/day\] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg/kg in the morning on Day 1 followed by total dose of 40 mg/kg/day (20 mg/kg in the morning and 20 mg/kg in the evening) on Days 4 to 10.

    Drug: Cannabidiol Oral Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) for Cannabidiol and Metabolite 7-hydroxy (7-OH) Cannabidiol

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.

    Time frame: Day 1 at age-specific times

  2. Cmax for Cannabidiol and Metabolite 7-OH Cannabidiol

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

    Time frame: Day 10 at age-specific times

  3. Dose Normalized Cmax (Cmax/D) for Cannabidiol and Metabolite 7-OH Cannabidiol

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17: Day 1 pre-dose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.

    Time frame: Day 1 at age-specific times

  4. Cmax/D for Cannabidiol and Metabolite 7-OH Cannabidiol

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

    Time frame: Day 10 at age-specific times

  5. Time to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.

    Time frame: Day 1 at age-specific times

  6. Time to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

    Time frame: Day 10 at age-specific times

  7. Half Life (t1/2) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

    Time frame: Day 1 at age-specific times

  8. Elimination Rate (Lambda-z [λz]) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

    Time frame: Day 1 at age-specific times

  9. Oral Clearance (CL/F) for Cannabidiol for Participants ≥2 Years of Age

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

    Time frame: Day 1 at age-specific times

  10. Volume of Distribution (Vz/F) of Cannabidiol for Participants ≥2 Years of Age

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

    Time frame: Day 1 at age-specific times

  11. Area Under the Plasma-Concentration Time Curve From 0 to 12 Hours Post-dose [AUC(0-12)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.

    Time frame: Day 1 at age-specific times

  12. Dose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.

    Time frame: Day 1 at age-specific times

  13. AUC From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] on Day 1 for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

    Time frame: Day 1 at age-specific times

  14. AUC From Time 0 to Infinity [AUC(0-inf)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

    Time frame: Day 1 at age-specific times

  15. Dose Normalized AUC(0-inf) [AUC(0-inf)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

    Time frame: Day 1 at age-specific times

  16. Metabolite (7-OH Cannabidiol) to Parent (Cannabidiol) Ratio for Cmax [MRCmax] on Day 1

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose. MRCmax was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).

    Time frame: Day 1 at age-specific times

  17. MRCmax on Day 10

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose. MRCmax was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).

    Time frame: Day 10 at age-specific times

  18. Metabolite to Parent Ratio for AUC(0-inf) [MRAUC(0-inf)] on Day 1 for Participants ≥2 Years of Age

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis. MRAUC(0-inf) was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).

    Time frame: Day 1 at age-specific times

  19. Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 1

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose. MRAUC(0-12) was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).

    Time frame: Day 1 at age-specific times

  20. Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 10

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose. MRAUC(0-12) was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).

    Time frame: Day 10 at age-specific times

  21. AUC(0-12) for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

    Time frame: Day 10 at age-specific times

  22. Dose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

    Time frame: Day 10 at age-specific times

  23. Minimum Plasma Concentration (Cmin) for Cannabidiol and Metabolite 7-OH Cannabidiol

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

    Time frame: Day 10 at age-specific times

  24. Average Plasma Concentration (Cavg) for Cannabidiol and Metabolite 7-OH Cannabidiol

    Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

    Time frame: Day 10 at age-specific times

  25. Accumulation Ratio for Cmax (RCmax) on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol

    RCmax is the ratio of Cmax at Day 10 compared to Cmax at Day 1. Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

    Time frame: Day 10 at age-specific times

  26. Accumulation Ratio for AUC(0-12) [RAUC(0-12)] on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol

    RAUC(0-12) is the ratio of AUC(0-12) at Day 10 compared to AUC(0-12) at Day 1. Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

    Time frame: Day 10 at age-specific times

  27. Time Linearity Index for Cannabidiol and Metabolite 7-OH Cannabidiol in Participants ≥2 Years of Age

    Time linearity index is calculated as the ratio of AUC(0-12) on Day 10/AUC\[0-inf\] on Day 1. Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

    Time frame: Day 1 and Day 10

  28. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product. It does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event not present prior to the initiation of the treatment or any event already present that worsens. Any laboratory (clinical chemistry, hematology, urinalysis), 12-lead electrocardiograms, vital signs (temperature, blood pressure, pulse rate, respiratory rate) and physical examination findings deemed by the investigator to be clinically significant were captured as AEs. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires the participant be at a risk of death at the time of the event, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, or other serious event that requires medical or surgical intervention.

    Time frame: From the first dose of study drug up to Day 17

  29. Clinical Global Impression of Improvement (CGI-I) Assessment

    The CGI-I was completed by the parents/caregivers and the investigator and was used to assess participants global status of their condition on Day 11 using a 7-point scale, where 1=very much improved and 7=very much worse since the initiation of treatment.

    Time frame: Day 11

  30. Change From Baseline in Clinical Global Impression of Severity (CGI-S) Assessment

    The CGI-S was completed by the parents/caregivers and the Investigator and was used to rate participant's mental illness status at Baseline (Screening) and Day 11 using a 7-point scale, where 1=normal, not mentally ill, and 7=among the most extremely mentally ill participants. This rating is based upon observed and reported symptoms, behavior, and function in the past seven days. The change in CGI-S score at Day 11 relative to Baseline is reported. A negative change from Baseline indicates improvement (decreased severity in illness).

    Time frame: Baseline and Day 11

  31. Change From Baseline in Daily Seizure Activity

    The specific number of tonic and atonic seizures per study day were recorded in a diary. The change in number of seizures at Day 11 relative to Baseline is reported. A negative change from Baseline indicates an improvement based on Daily Seizure Activity.

    Time frame: Baseline and Day 11

  32. Number of Participants With Suicide Related Thoughts and Behaviors Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS captured the occurrence, severity, and frequency of suicide related thoughts and behaviors at Day 11. The C-SSRS was only used for participants ≥ 7 years of age. The number of participants with results of "Yes" for Suicidal Ideation (Wish to be Dead and Non-Specific Active Suicidal Thoughts) and Suicidal Behavior (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior, and Suicidal Behavior) are reported.

    Time frame: Day 11

07

Results

Posted Jun 23, 2017

Participant flow

Participant flow — Overall Study
MilestoneLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Started202021
Completed202021
Not completed000

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) for Cannabidiol and Metabolite 7-hydroxy (7-OH) Cannabidiol

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.

Time frame:
Day 1 at age-specific times
Reported as:
Mean · nanograms/milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) for Cannabidiol and Metabolite 7-hydroxy (7-OH) Cannabidiol
nanograms/milliliter (ng/mL)Low Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol59.03 ± 99.98110.5 ± 142.3256.9 ± 351.9
7-OH Cannabidiol28.71 ± 26.7261.89 ± 72.88140.9 ± 210.0
PrimaryCmax for Cannabidiol and Metabolite 7-OH Cannabidiol

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

Time frame:
Day 10 at age-specific times
Reported as:
Mean · ng/mL
Cmax for Cannabidiol and Metabolite 7-OH Cannabidiol
ng/mLLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol119.6 ± 105.0220.0 ± 294.7426.8 ± 327.7
7-OH Cannabidiol79.38 ± 40.82136.6 ± 140.9286.1 ± 201.9
PrimaryDose Normalized Cmax (Cmax/D) for Cannabidiol and Metabolite 7-OH Cannabidiol

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17: Day 1 pre-dose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.

Time frame:
Day 1 at age-specific times
Reported as:
Mean · ng/mL/(mg/kg)
Dose Normalized Cmax (Cmax/D) for Cannabidiol and Metabolite 7-OH Cannabidiol
ng/mL/(mg/kg)Low Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol11.72 ± 19.8910.77 ± 13.9713.25 ± 18.07
7-OH Cannabidiol5.737 ± 5.3305.990 ± 7.0117.286 ± 10.91
PrimaryCmax/D for Cannabidiol and Metabolite 7-OH Cannabidiol

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

Time frame:
Day 10 at age-specific times
Reported as:
Mean · ng/mL/(mg/kg)
Cmax/D for Cannabidiol and Metabolite 7-OH Cannabidiol
ng/mL/(mg/kg)Low Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol23.79 ± 20.4621.16 ± 28.4021.40 ± 16.38
7-OH Cannabidiol15.82 ± 7.92813.10 ± 13.0614.39 ± 10.26
PrimaryTime to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.

Time frame:
Day 1 at age-specific times
Reported as:
Median · hours (h)
Time to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol
hours (h)Low Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol2.58 (1.02 to 8.00)4.00 (1.00 to 8.08)3.15 (1.00 to 24.02)
7-OH Cannabidiol2.55 (1.00 to 6.08)4.00 (1.00 to 11.95)3.07 (1.00 to 12.05)
PrimaryTime to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

Time frame:
Day 10 at age-specific times
Reported as:
Median · h
Time to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol
hLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol2.99 (1.00 to 4.25)2.00 (0.00 to 6.00)3.00 (0.00 to 6.02)
7-OH Cannabidiol2.08 (1.00 to 4.08)2.03 (1.00 to 6.05)2.03 (0.00 to 5.90)
PrimaryHalf Life (t1/2) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

Time frame:
Day 1 at age-specific times
Reported as:
Mean · h
Half Life (t1/2) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age
hLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol31.31 ± 23.4633.48 ± 14.9721.58 ± 10.50
7-OH Cannabidiol19.71 ± 7.64031.84 ± 24.2814.77 ± 4.354
PrimaryElimination Rate (Lambda-z [λz]) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

Time frame:
Day 1 at age-specific times
Reported as:
Mean · 1/h
Elimination Rate (Lambda-z [λz]) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age
1/hLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol0.02969 ± 0.013860.02836 ± 0.023400.03949 ± 0.01976
7-OH Cannabidiol0.04053 ± 0.015570.03276 ± 0.019850.05123 ± 0.01711
PrimaryOral Clearance (CL/F) for Cannabidiol for Participants ≥2 Years of Age

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

Time frame:
Day 1 at age-specific times
Reported as:
Mean · Liters (L)/h/kg
Oral Clearance (CL/F) for Cannabidiol for Participants ≥2 Years of Age
Liters (L)/h/kgLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Oral Clearance (CL/F) for Cannabidiol for Participants ≥2 Years of Age29.78 ± 15.9621.10 ± 23.0431.29 ± 30.43
PrimaryVolume of Distribution (Vz/F) of Cannabidiol for Participants ≥2 Years of Age

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

Time frame:
Day 1 at age-specific times
Reported as:
Mean · L/kg
Volume of Distribution (Vz/F) of Cannabidiol for Participants ≥2 Years of Age
L/kgLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Volume of Distribution (Vz/F) of Cannabidiol for Participants ≥2 Years of Age1021 ± 609.1930.8 ± 1034982.6 ± 1119
PrimaryArea Under the Plasma-Concentration Time Curve From 0 to 12 Hours Post-dose [AUC(0-12)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.

Time frame:
Day 1 at age-specific times
Reported as:
Mean · ng*h/mL
Area Under the Plasma-Concentration Time Curve From 0 to 12 Hours Post-dose [AUC(0-12)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1
ng*h/mLLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol173.9 ± 179.6507.1 ± 687.7914.5 ± 1155
7-OH Cannabidiol124.4 ± 80.18329.8 ± 402.9646.7 ± 886.3
PrimaryDose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.

Time frame:
Day 1 at age-specific times
Reported as:
Mean · ng*h/mL
Dose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1
ng*h/mLLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol34.60 ± 35.4849.23 ± 66.6847.13 ± 59.38
7-OH Cannabidiol24.88 ± 15.9331.77 ± 38.0033.39 ± 45.94
PrimaryAUC From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] on Day 1 for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

Time frame:
Day 1 at age-specific times
Reported as:
Mean · ng*h/mL
AUC From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] on Day 1 for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age
ng*h/mLLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol250.0 ± 217.1692.5 ± 826.91355 ± 1447
7-OH Cannabidiol212.2 ± 112.1544.9 ± 526.61221 ± 1296
PrimaryAUC From Time 0 to Infinity [AUC(0-inf)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

Time frame:
Day 1 at age-specific times
Reported as:
Mean · ng*h/mL
AUC From Time 0 to Infinity [AUC(0-inf)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age
ng*h/mLLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol270.1 ± 256.71140 ± 11181584 ± 1709
7-OH Cannabidiol229.3 ± 122.3704.1 ± 627.81354 ± 1428
PrimaryDose Normalized AUC(0-inf) [AUC(0-inf)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

Time frame:
Day 1 at age-specific times
Reported as:
Mean · ng*h/mL/(mg/kg)
Dose Normalized AUC(0-inf) [AUC(0-inf)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age
ng*h/mL/(mg/kg)Low Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol53.64 ± 50.04111.8 ± 111.283.10 ± 87.93
7-OH Cannabidiol46.07 ± 24.6368.43 ± 62.3470.34 ± 73.66
PrimaryMetabolite (7-OH Cannabidiol) to Parent (Cannabidiol) Ratio for Cmax [MRCmax] on Day 1

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose. MRCmax was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).

Time frame:
Day 1 at age-specific times
Reported as:
Mean · ratio
Metabolite (7-OH Cannabidiol) to Parent (Cannabidiol) Ratio for Cmax [MRCmax] on Day 1
ratioLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Metabolite (7-OH Cannabidiol) to Parent (Cannabidiol) Ratio for Cmax [MRCmax] on Day 10.8935 ± 0.55430.9328 ± 0.83320.8081 ± 0.4849
PrimaryMRCmax on Day 10

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose. MRCmax was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).

Time frame:
Day 10 at age-specific times
Reported as:
Mean · ratio
MRCmax on Day 10
ratioLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
MRCmax on Day 100.7717 ± 0.39600.8230 ± 0.38800.7657 ± 0.4179
PrimaryMetabolite to Parent Ratio for AUC(0-inf) [MRAUC(0-inf)] on Day 1 for Participants ≥2 Years of Age

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis. MRAUC(0-inf) was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).

Time frame:
Day 1 at age-specific times
Reported as:
Mean · ratio
Metabolite to Parent Ratio for AUC(0-inf) [MRAUC(0-inf)] on Day 1 for Participants ≥2 Years of Age
ratioLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Metabolite to Parent Ratio for AUC(0-inf) [MRAUC(0-inf)] on Day 1 for Participants ≥2 Years of Age0.9099 ± 0.51730.9459 ± 0.48740.9538 ± 0.4370
PrimaryMetabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 1

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose. MRAUC(0-12) was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).

Time frame:
Day 1 at age-specific times
Reported as:
Mean · ratio
Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 1
ratioLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 10.9309 ± 0.52290.9793 ± 0.71470.9085 ± 0.5075
PrimaryMetabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 10

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose. MRAUC(0-12) was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).

Time frame:
Day 10 at age-specific times
Reported as:
Mean · ratio
Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 10
ratioLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 100.8795 ± 0.40840.7866 ± 0.23610.8700 ± 0.4304
PrimaryAUC(0-12) for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

Time frame:
Day 10 at age-specific times
Reported as:
Mean · ng*h/mL
AUC(0-12) for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10
ng*h/mLLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol581.6 ± 283.41098 ± 976.42708 ± 1789
7-OH Cannabidiol513.4 ± 269.0832.8 ± 675.22165 ± 1405
PrimaryDose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

Time frame:
Day 10 at age-specific times
Reported as:
Mean · ng*h/mL/(mg/kg)
Dose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10
ng*h/mL/(mg/kg)Low Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol115.8 ± 55.32106.0 ± 94.64135.7 ± 89.17
7-OH Cannabidiol102.2 ± 53.0180.19 ± 63.53108.7 ± 70.76
PrimaryMinimum Plasma Concentration (Cmin) for Cannabidiol and Metabolite 7-OH Cannabidiol

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

Time frame:
Day 10 at age-specific times
Reported as:
Mean · ng/mL
Minimum Plasma Concentration (Cmin) for Cannabidiol and Metabolite 7-OH Cannabidiol
ng/mLLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol19.97 ± 8.79841.67 ± 25.41118.3 ± 75.82
7-OH Cannabidiol21.82 ± 13.2334.11 ± 23.99108.7 ± 70.87
PrimaryAverage Plasma Concentration (Cavg) for Cannabidiol and Metabolite 7-OH Cannabidiol

Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

Time frame:
Day 10 at age-specific times
Reported as:
Mean · ng/mL
Average Plasma Concentration (Cavg) for Cannabidiol and Metabolite 7-OH Cannabidiol
ng/mLLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol48.56 ± 23.5891.38 ± 80.92225.7 ± 149.3
7-OH Cannabidiol42.94 ± 22.5469.37 ± 56.09180.4 ± 117.1
PrimaryAccumulation Ratio for Cmax (RCmax) on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol

RCmax is the ratio of Cmax at Day 10 compared to Cmax at Day 1. Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

Time frame:
Day 10 at age-specific times
Reported as:
Mean · ratio
Accumulation Ratio for Cmax (RCmax) on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol
ratioLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol5.535 ± 5.5514.454 ± 4.4667.488 ± 11.93
7-OH Cannabidiol3.823 ± 2.7303.996 ± 3.5445.788 ± 6.028
PrimaryAccumulation Ratio for AUC(0-12) [RAUC(0-12)] on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol

RAUC(0-12) is the ratio of AUC(0-12) at Day 10 compared to AUC(0-12) at Day 1. Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.

Time frame:
Day 10 at age-specific times
Reported as:
Mean · ratio
Accumulation Ratio for AUC(0-12) [RAUC(0-12)] on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol
ratioLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol5.434 ± 3.6255.489 ± 4.6339.376 ± 15.11
7-OH Cannabidiol4.865 ± 2.7484.524 ± 3.3387.541 ± 7.187
PrimaryTime Linearity Index for Cannabidiol and Metabolite 7-OH Cannabidiol in Participants ≥2 Years of Age

Time linearity index is calculated as the ratio of AUC(0-12) on Day 10/AUC\[0-inf\] on Day 1. Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.

Time frame:
Day 1 and Day 10
Reported as:
Mean · ratio
Time Linearity Index for Cannabidiol and Metabolite 7-OH Cannabidiol in Participants ≥2 Years of Age
ratioLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Cannabidiol3.211 ± 2.0482.628 ± 2.2764.201 ± 4.990
7-OH Cannabidiol2.500 ± 0.93651.821 ± 1.1623.045 ± 2.260
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product. It does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event not present prior to the initiation of the treatment or any event already present that worsens. Any laboratory (clinical chemistry, hematology, urinalysis), 12-lead electrocardiograms, vital signs (temperature, blood pressure, pulse rate, respiratory rate) and physical examination findings deemed by the investigator to be clinically significant were captured as AEs. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires the participant be at a risk of death at the time of the event, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, or other serious event that requires medical or surgical intervention.

Time frame:
From the first dose of study drug up to Day 17
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
TEAE13917
SAE012
PrimaryClinical Global Impression of Improvement (CGI-I) Assessment

The CGI-I was completed by the parents/caregivers and the investigator and was used to assess participants global status of their condition on Day 11 using a 7-point scale, where 1=very much improved and 7=very much worse since the initiation of treatment.

Time frame:
Day 11
Reported as:
Mean · scores on a scale
Clinical Global Impression of Improvement (CGI-I) Assessment
scores on a scaleLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Parents/Caregivers2.1 ± 1.022.4 ± 0.822.3 ± 1.15
Investigator2.7 ± 0.922.5 ± 0.942.9 ± 0.91
PrimaryChange From Baseline in Clinical Global Impression of Severity (CGI-S) Assessment

The CGI-S was completed by the parents/caregivers and the Investigator and was used to rate participant's mental illness status at Baseline (Screening) and Day 11 using a 7-point scale, where 1=normal, not mentally ill, and 7=among the most extremely mentally ill participants. This rating is based upon observed and reported symptoms, behavior, and function in the past seven days. The change in CGI-S score at Day 11 relative to Baseline is reported. A negative change from Baseline indicates improvement (decreased severity in illness).

Time frame:
Baseline and Day 11
Reported as:
Mean · scores on a scale
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Assessment
scores on a scaleLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Parents/Caregivers-1.7 ± 2.08-2.2 ± 2.04-1.8 ± 1.64
Investigator-1.1 ± 1.27-0.7 ± 1.15-0.7 ± 1.23
PrimaryChange From Baseline in Daily Seizure Activity

The specific number of tonic and atonic seizures per study day were recorded in a diary. The change in number of seizures at Day 11 relative to Baseline is reported. A negative change from Baseline indicates an improvement based on Daily Seizure Activity.

Time frame:
Baseline and Day 11
Reported as:
Mean · number of seizures per day
Change From Baseline in Daily Seizure Activity
number of seizures per dayLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Number of Tonic Seizures-0.8 ± 1.55-0.8 ± 1.59-2.9 ± 7.69
Number of Atonic Seizures-0.2 ± 0.98-0.1 ± 0.280.0 ± 0.00
PrimaryNumber of Participants With Suicide Related Thoughts and Behaviors Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

The C-SSRS captured the occurrence, severity, and frequency of suicide related thoughts and behaviors at Day 11. The C-SSRS was only used for participants ≥ 7 years of age. The number of participants with results of "Yes" for Suicidal Ideation (Wish to be Dead and Non-Specific Active Suicidal Thoughts) and Suicidal Behavior (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior, and Suicidal Behavior) are reported.

Time frame:
Day 11
Reported as:
Count of participants · Participants
Number of Participants With Suicide Related Thoughts and Behaviors Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
Suicide Ideation000
Suicide Behavior000

Adverse events

Collected over From the first dose of study drug to 7 days after the last dose of study drug (up to Day 17). Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose Cannabidiol Oral Solution [10 mg/kg/Day]0/20 (0%)0/20 (0%)13/20 (65%)
Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]0/20 (0%)1/20 (5%)9/20 (45%)
High Dose Cannabidiol Oral Solution [40 mg/kg/Day]0/21 (0%)2/21 (9.5%)17/21 (81%)
Most frequent serious events
Most frequent serious events
EventLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
ThrombophlebitisVascular disorders0/201/200/21
ApnoeaRespiratory, thoracic and mediastinal disorders0/200/201/21
Drug eruptionSkin and subcutaneous tissue disorders0/200/201/21
Most frequent other events
Showing 10 of 66
Most frequent other events
EventLow Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]
DiarrhoeaGastrointestinal disorders1/202/207/21
SomnolenceNervous system disorders3/203/207/21
AnaemiaBlood and lymphatic system disorders2/205/204/21
FlatulenceGastrointestinal disorders0/202/203/21
Psychomotor hyperactivityNervous system disorders0/202/203/21
Abdominal pain upperGastrointestinal disorders2/201/200/21
VomitingGastrointestinal disorders2/201/200/21
Catheter site pruritusGeneral disorders0/202/201/21
Decreased appetiteMetabolism and nutrition disorders2/200/201/21
Dermatitis contactSkin and subcutaneous tissue disorders0/202/200/21

Baseline characteristics

Safety Analysis Population (SAF), all participants who received ≥1 dose of the investigational product.

Age, Continuous
Age, Continuous(years)Low Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]Total
Mean7.5 ± 5.327.7 ± 5.177.8 ± 5.397.6 ± 5.21
Age, Customized
Age, Customized(Participants)Low Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]Total
Infants = 1 to <2 years55515
Children = 2 to <12 years991028
Adolescents = 12 to ≤17 years66618
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]Total
Female1071128
Male10131033
Region of Enrollment
Region of Enrollment(Participants)Low Dose Cannabidiol Oral Solution [10 mg/kg/Day]Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day]High Dose Cannabidiol Oral Solution [40 mg/kg/Day]Total
United States20202161
08

Study locations

10 sites
  • University of California San Francisco Medical Center
    San Francisco, California 94143, United States
  • Miami Children's Hospital
    Miami, Florida 33155, United States
  • Child Neurology Center - NW F
    Pensacola, Florida 32504, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Clinical Research Center of Nevada LLC
    Las Vegas, Nevada 89104, United States
  • Oregon Health Services University
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38103, United States
  • Texas Scottish Rite Hospital for Children
    Dallas, Texas 79219, United States
  • Mary Bridge Children's Hospital
    Tacoma, Washington 98403, United States
09

References and documents

Publications

  • Wheless JW, Dlugos D, Miller I, Oh DA, Parikh N, Phillips S, Renfroe JB, Roberts CM, Saeed I, Sparagana SP, Yu J, Cilio MR; INS011-14-029 Study Investigators. Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy. CNS Drugs. 2019 Jun;33(6):593-604. doi: 10.1007/s40263-019-00624-4. PubMed 31049885 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in May 2016, 12 months.

Results were first posted in Jun 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2014
First posted
Dec 24, 2014
StartActual
Apr 13, 2015
Primary completionActual
May 9, 2016
CompletionActual
May 9, 2016
Results first posted
Jun 23, 2017
Last update
Jun 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02324673
Responsible party
Sponsor
First posted
Dec 24, 2014
Start date
Apr 13, 2015
Primary completion
May 9, 2016
Completion
May 9, 2016
Results posted
Jun 23, 2017
Last update
Jun 23, 2017

Study contacts

Neha Parikh
study director · INSYS Therapeutics Inc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion